side effects include:
nausea
vomiting
diarrhea
abdominal pain/discomfort
disorder
rash
paresthesia
oral/perioral

gastrointestinal side effects
skin rashes
frequent side effects in clinical trials of amprenavir
active ingredient
agenerase
combination with other antiretrovirals
gastrointestinal effects
nausea
vomiting
diarrhea
abdominal pain
discontinuation of amprenavir during the first weeks of treatment
skin rashes
median onset
duration
days
discontinuation of amprenavir
patients
gastrointestinal side effects
nausea
vomiting
diarrhea
loose stools in clinical trials
amprenavir
active ingredient
agenerase
lamivudine
zidovudine in therapy-naive patients
incidence
therapy-naive patients
administered lamivudine
zidovudine
abdominal symptoms
anorexia
patients
receiving amprenavir in combination with ritonavir
other antiretrovirals
rashes
intensity
pruritus
onset of rash development
days
days
amprenavir
active ingredient
agenerase
moderate rash
rash
drug
amprenavir
life-threatening rashes
moderate rashes
systemic symptoms
dermatologic side effects
skin rash
hiv
infected patients
amprenavir in all multidose studies
life-threatening rash
including
stevens-johnson syndrome
patients
metabolic side effects
hyperglycemia
hypertriglyceridemia
hypercholesterolemia in clinical trials
amprenavir
active ingredient
agenerase
lamivudine
zidovudine in therapy-naive nonfasting patients
incidence
therapy-naive nonfasting patients
administered lamivudine
zidovudine
grade
hypertriglyceridemia
hyperglycemia
patients
receiving amprenavir in combination with ritonavir
new onset
exacerbation
preexisting diabetes mellitus
elevated serum creatine kinase
ketoacidosis
hepatic side effects
elevations in ast
times uln
alt
times uln
amylase
times uln
patients
receiving amprenavir
active ingredient
agenerase
combination with ritonavir
nervous system
side effects
oral/perioral paresthesia
other paresthesias
including
peripheral paresthesias
clinical trials
amprenavir
active ingredient
agenerase
lamivudine
zidovudine in therapy-naive patients
incidence
therapy-naive patients
administered lamivudine
zidovudine
headache
patients
receiving amprenavir in combination with ritonavir
other antiretrovirals
psychiatric side effects
depression
mood disorder
therapy-naive patients
administered amprenavir
active ingredient
agenerase
lamivudine
zidovudine in clinical trials
incidence
therapy-naive patients
administered lamivudine
zidovudine
hematologic side effects
neutropenia
hemolytic anemia
hematologic side effects
protease inhibitors
spontaneous bleeding in patients with hemophilia a
b.
reported cases
treatment with protease inhibitors
patients
additional factor
causal relationship between protease inhibitor therapy
episodes
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
breast enlargement
cushingoid appearance
patients
receiving protease inhibitors
mechanism
long-term consequences of these events
causal relationship
case
reduction of neck
fat disposition
buffalo hump
amprenavir
active ingredient
agenerase
indinavir in a regimen
other side effects
taste disorders
therapy-naive patients
administered amprenavir with lamivudine
zidovudine in clinical trials
incidence
therapy-naive patients
administered lamivudine
zidovudine
fatigue
chills
patients
receiving amprenavir in combination with ritonavir
other antiretrovirals
hypersensitivity side effects
urticaria